| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Revenues | ||||||
0 | 0 | 0 | - | |||
Revenues | ||||||
- | - | - | 0 | |||
Operating expenses: | ||||||
Research and development | ||||||
11,013 | 9,728 | 4,545 | 1,496 | |||
General and administrative | ||||||
6,312 | 5,229 | 4,090 | 2,381 | |||
Depreciation and amortization | ||||||
199 | 68 | 18 | 6 | |||
Total operating expenses | ||||||
17,524 | 15,025 | 8,653 | 3,883 | |||
Loss from operations | ||||||
-17,524 | -15,025 | -8,653 | -3,883 | |||
Other income: | ||||||
Gain from change in fair value of warrant liability | ||||||
-4,062 | -3,185 | 2,548 | 0 | |||
Gain from settlement of liability | ||||||
- | - | 149 | 0 | |||
Gain from expiration of warrants | ||||||
- | - | 1,238 | 0 | |||
Other income, net | ||||||
15 | -40 | 9 | - | |||
Other income | ||||||
- | - | - | 0 | |||
Interest income, net | ||||||
13 | 4 | 0 | - | |||
Net loss before taxes | ||||||
-13,434 | -11,876 | - | - | |||
Income tax benefit | ||||||
-229 | 0 | - | - | |||
Interest expense, net | ||||||
- | - | - | 43 | |||
Net loss | ||||||
-13,205 | -11,876 | -9,805 | -3,926 | |||
Net loss per common share - basic and diluted (in dollars per share) | ||||||
-0.32 | -0.46 | -0.53 | -0.40 | |||
Weighted average common shares outstanding, basic and diluted (in shares) | ||||||
40,721 | 25,904 | 18,569 | 9,827 | |||
Comprehensive loss: | ||||||
Net loss | ||||||
-13,205 | -11,876 | -9,805 | - | |||
Other comprehensive income (loss): | ||||||
Foreign currency translation | ||||||
-4 | 35 | 0 | - | |||
Comprehensive loss | ||||||
-13,209 | -11,841 | -9,805 | - | |||